-
Condition → preferred treatment
-
Alcohol withdrawal
Benzodiazepines
-
-
ADHD
- Methylphenidate
- amphetamines
-
Bipolar disorder
- "Mood stabilizers"
- -Lithium
- -valproid acid
- -carbamazepine
Atypical antipsychotics
-
-
Depression
- SSRIs
- SNRIs
- TCAs
- buspirone
- mirtazapine (especially with insomnia)
-
Obsessive-compulsive disorder
-
Panic disorder
- SSRIs
- venlafaxine
- benzodiazepines
-
-
Schizophrenia
Antipsychotics
-
-
Tourette's syndrome
Antipsychotics (e.g., haloperidol, risperidone)
-
CNS stimulants
mechanism, clinical use
Methylphenidate, dextroamphetamine, methamphetamine
- Mechanism:
- -↑ catecholamines at the synaptic cleft, especially NE and dopamine
- Clinical use:
- -ADHD
- -Narcolepsy
- -Appetite control
-
Antipsychotics (neuroleptics)
Mechanism, clinical use, toxicity
Haloperidol, trifluoperazine, fluphenazine, thioridazine, chlorpromazine ( haloperidol + "-azines")
- Mechanism:
- -All typical antipsychotics block dopamine D2 receptors (↑ [cAMP])
- Clinical use:
- -Schizophrenia (primarily positive symptoms)
- -psychosis
- -acute mania
- -Tourette's syndrome
- Toxicity:
- -lipid soluble, stored in body fat → slowly removed from body
- -Extrapyramidal system (EPS) side effects: dyskinesias
- -Endocrine side effects: dopamine receeptor antagonism → hyperprolactinemia → galactorrhea
- -Blocking muscarinic receptors: dry mouth, constipation
- -Blocking α1 receptors: hypotension
- -Blocking histamine: sedation
- -Neuroleptic malignant syndrome
- -Tardive dyskinesia
-
Extrapyramidal system (EPS) side effects
evolution of EPS side effects
- 4 hr acute dystonia (muscle spasm, stiffness, oculogyric crisis)
- 4 day akathisia (restlessness)
- 4 week bradykinesia (parkinsonism)
- 4 mo tardive dyskinesia
-
Neuroleptic malignant syndrome (NMS)
- Rigidity, myoglobinuria, autonomic instability, hyperpyrexia
- Tx: dantrolene, D2 agonist (e.g., bromocriptine)
- *Think FEVER:
- -Fever
- -Encephalopathy
- -Vitals unstable
- -Elevated enzymes
- -Rigidity of muscles
-
Tardive dyskinesia
- Stereotypic oral-facial movements as a result of long-term antipsychotic use
- Often irreversible
-
Antipsychotics
High vs low potency
- High potency: Trifluoperazine, Fluphenazine, Haloperidol (Try to Fly High)
- - neurologic side effects (extrapyramidal symptoms)
- Low potency: Chlorpromazine, Thioridazine (Cheating Thieves are low)
- - non-neurologic side effects (anticholinergic, antihistamine, and α1-blockade effects)
-
Atypical antipsychotics (2nd generation)
Mechanism, clinical use, toxicity
- Olanzapine, clozapine, quetiapine, resperidone, aripiprazole, ziprasidone
- *It's atypical for old closets to quietly risper from A to Z
- Mechanism: not completely understood
- -Varied effects on 5-HT2, dopamine, and α- and H1-receptors
- Clinical use:
- -Schizophrenia (both positive and negative symptoms)
- -Bipolar disorder
- -OCD
- -Anxiety disorder
- -Depression
- -Mania
- -Tourette's syndrome
- Toxicity:
- -Fewer extrapyramidal and anticholinergic side effects than traditional antipsychotics
- -Olanzapine/clozapine: weight gain
- -Clozapine: agranulocytosis (monitor WBC count weekly), seizures
- -Ziprasidone: prolong QT interval
-
MBB
first generation vs second generation
- Second generation antipsychotic drugs:
- -fewer "extrapyramidal" AEs
- -more effective for negative symptoms
- -less elevation of prolactin
- -Metabolic syndrome
- First generation antipsychotic drugs:
- -Extrapyramidal side effects (parkinsonism)
- -dystonia, akathisia, parkinsonian syndrome
-
Lithium
mechanism, clinical use, toxicity
Mechanism: not known
- Clinical use: mood stabilizer
- -bipolar disorder (blocks relapse and acute manic events
- -SIADH
- Toxicity:
- LMNOP-Lithium side effects:
- -Movement (tremor)
- -Nephrogenic diabetes insipidus
- -HypOthyroidism
- -Pregnancy problems
- -sedation
- -edema
- -heart block
- -polyuria (ADH antagonist → nephrogenic DI)
- -Fetal cardiac defects: Ebstein anomaly, malformation of great vessels
- *Narrow therapeutic window; monitor serum levels closely
- Excretion: kidney (most is reabsorbed at proximal convoluted tubules following Na+ reabsorption)
-
Buspirone
Mechanism, clinical use
Mechanism: Stimulates 5-HT 1A receptors
- Clinical use:
- -Generalized anxiety disorder
- -Does not cause sedation, addiction, or tolerance
- -Takes 1-2 weeks to take effect
- -No interaction with alcohol (vs. barbiturates, benzodiazepines)
*I'm always anxious if the bus will be on time, so I take buspir one
-
- Antidepressants mechanism of action
- NE reuptake: SNRIs, Desipramine, maprotiline
- 5-HT reuptake: Fluoxetine, trazodone
- α2-receptor: Mirtazapine
- MAO inhibitors
-
SSRIs
Mechanism, clinical use, toxicity
- Fluoxetine, paroxetine, sertraline, citalopram
- *Flashbacks paralyze senior citizens
Mechanism: Serotonin-specific reuptake inhibitor
- Clinical use: normally takes 4-8 weeks for antidepressants to have an effect
- -Depression
- -Generalized anxiety disorder
- -Panic disorder
- -OCD
- -Bulimia
- -Social phobias
- -PTSD
- Toxicity:
- -Fewer than TCAs
- -GI distress, sexual dysfunction (anorgasmia, ↓ libido)
- -Serotonin syndrome: any drug that ↑ serotonin (MAO inhibitors, SNRIs, TCAs)
- - hyperthermia, confusion, myoclonus, cardiovascular collapse, flushing, diarrhea, seizures
- - Tx: cyproheptadine (5-HT2 receptor antagonist)
-
SNRIs
Mechanism, clinical use, toxicity
Venlafaxine, duloxetine
Mechanism: Inhibit serotonin and NE reuptake
- Clinical use:
- -Depression
- -Venlafaxine: also used in generalized anxiety and panic disorders
- -Duloxetine: diabetic peripheral neuropathy
- -Duloxetine has greater effect on NE
- Toxicity:
- - ↑ BP most common
- - stimulant effects
- - sedation
- - nausea
-
Tricyclinc antidepressants (TCAs)
Mechanism, clinical use, toxicity
Amitriptyline, nortriptyline, imapramine, desipramine, clomipramine, doxepin, amoxapine ("-iptyline" or "-ipramine")
- Mechanism:
- -Block reuptake of NE and serotonin
- Clinical use:
- -Major depression
- -bedwetting (imipramine)
- -OCP (clomipramine)
- -Fibromyalgia
- Toxicity:
- -anti-histamine side effects: sedation
- -α1-blocking effects: postural hypotension
- -anticholinergic side effects (tachycardia, urinary retention, dry mouth) (amitriptyline > nortriptyline)
- -Tri-C's: Convulsions, Coma, Cardiotoxicyity (arrhythmias)
- -respiratory depression
- -hyperpyrexia
- -Confusion and hallucinations in elderly (use nortriptyline)
Tx: NaHCO 3 for cardiovascular toxicity
-
Monoamine oxidase (MAO) inhibitors
mechanism, clinical use, toxicity
- Tranylcypromine, Phenelzine, Isocarboxazid, Selegiline (selective MAO-B inhibitors)
- **MAO Takes Pride In Shanghai
- Mechanism:
- -Nonselective MAO inhibition ↑ levels of amine neurotransmitters (NE, serotonin, dopamine)
- Clinical use:
- -Atypical depression
- -Anxiety
- -Hypochondriasis
- Toxicity:
- -Hypertensive crisis ( with ingestion of tyramine - wine and cheese)
- -CNS stimulation
- -Contraindicated with SSRIs, TCAs, St. John's Wort, meperidine, dextromethorphan (prevent serotonin syndrome)
-
Atypical antidepressants
- Bupropion
- Mirtazapine
- Maprotiline
- Trazodone
-
Bupropion
- Mechanism: unknown → ↑ NE and dopamine
- Toxicity: stimulant effect (tachycardia, insomnia), headache, seizures in bulimic patients
- *No sexual side effects
- Other uses: smoking cessation
-
Mirtazapine
- Mechanism:
- -α2-antagonist (↑ release of NE and serotonin)
- -potent 5-HT2 and 5-HT3 receptor antagonist
Toxicity: sedation (desirable in depressed pts with insomnia), ↑ appetite, weight gain, dry mouth
-
Maprotiline
- Mechanism: Blocks NE reuptake
- Toxicity: sedation, orthostatic hypotension
-
Trazodone
- Mechanism: Primarily inhibits serotonin reuptake
- Clinical use: insomnia
- -High doses needed for antidepressant effects
- Toxicity: sedation, nausea, priapism, postural hypotension
- *Trazobone due to male-specific side effects
|
|